Eli Lilly and Company

CompanyUnited States

Eli Lilly and Company develops 18 assets, the furthest approved (donanemab in Alzheimer's disease). Mostly small molecule and peptide acting on Insulin/IGF-1 signalling, GLP1R and lipid and ceramide metabolism; based in the United States.

Assets
18
Furthest
Approved
Trials
476
Signals
11

Pipeline

18

  • donanemab

    Monoclonal antibody targeting N3pG-beta-amyloid to promote clearance of amyloid plaques.

    ApprovedAntibodyAPPProteostasisAlzheimer's diseaseamyloid pathology

  • dulaglutide

    GLP-1 receptor agonist that enhances glucose-dependent insulin secretion.

    ApprovedProtein or enzymeInsulin/IGF-1 signallingGLP1Rcardiovascular diseasecardiovascular events

  • empagliflozin

    Inhibits renal SGLT2 to reduce glucose reabsorption and lower blood glucose

    ApprovedSmall moleculeAMPK signallingAutophagycardiovascular deathcardiovascular disease

15 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms11
  • Trials692
  • Signals20
  • Integrity notices3
  • Similar companies6

Papers

Updated 7 Oct 2026 · 296 sources

Intelligence